Home Amines 1009820-21-6
1009820-21-6,MFCD13184796
Catalog No.:AA00039R

1009820-21-6 | 5-[(3-Chlorophenyl)amino]benzo[c]2,6-naphthyridine-8-carboxylic acid

Pack Size
Purity
Availability
Price(USD)
Quantity
  
1mg
98%
in stock  
$8.00   $6.00
- +
5mg
98%
in stock  
$19.00   $13.00
- +
50mg
98%
in stock  
$84.00   $59.00
- +
100mg
98%
in stock  
$116.00   $81.00
- +
250mg
98%
in stock  
$206.00   $144.00
- +
1g
95%
in stock  
$808.00   $565.00
- +
  • Technical Information
  • Properties
  • Downstream Synthesis Route
  • Literature
  • Request for Quotation
  • Download SDS
  • Technical Information
  • Properties
  • Downstream Synthesis Route
  • Literature
Technical Information
Catalog Number:
AA00039R
Chemical Name:
5-[(3-Chlorophenyl)amino]benzo[c]2,6-naphthyridine-8-carboxylic acid
CAS Number:
1009820-21-6
Molecular Formula:
C19H12ClN3O2
Molecular Weight:
349.7705
MDL Number:
MFCD13184796
SMILES:
Clc1cccc(c1)Nc1nc2cc(ccc2c2c1ccnc2)C(=O)O
Properties
Computed Properties
 
Complexity:
491  
Covalently-Bonded Unit Count:
1  
Heavy Atom Count:
25  
Hydrogen Bond Acceptor Count:
5  
Hydrogen Bond Donor Count:
2  
Rotatable Bond Count:
3  
XLogP3:
4.4  

Downstream Synthesis Route

[1]CurrentPatentAssignee:SENHWABIOSCIENCES-WO2008/28168,2008,A2Locationinpatent:Page/Pagecolumn62-63

[2]CurrentPatentAssignee:SENHWABIOSCIENCES-US2009/239859,2009,A1Locationinpatent:Page/Pagecolumn26

[3]Wang,Yuanjiang;Wang,Xinyi;Xu,Gang;Gou,Shaohua[JournalofMedicinalChemistry,2021,vol.64,#7,p.4163-4178]Wang,Yuanjiang;Lv,Zhaodan;Chen,Feihong;Wang,Xing;Gou,Shaohua[JournalofMedicinalChemistry,2021,vol.64,#8,p.5082-5098]

[1]Locationinpatent:schemeortablePierre,Fabrice;Stefan,Eric;Nédellec,Anne-Sophie;Chevrel,Marie-Claire;Regan,CollinF.;Siddiqui-Jain,Adam;MacAlino,Diwata;Streiner,Nicole;Drygin,Denis;Haddach,Mustapha;O'Brien,SeanE.;Anderes,Kenna;Ryckman,DavidM.[BioorganicandMedicinalChemistryLetters,2011,vol.21,#22,p.6687-6692]

[1]CurrentPatentAssignee:SOUTHEASTUNIVERSITY-CN105622674,2016,ALocationinpatent:Paragraph0053;0054;0056;0072;0073;0074

[1]Chen,Hong;Chen,Feihong;Liu,Nannan;Wang,Xinyi;Gou,Shaohua[BioorganicChemistry,2018,vol.81,p.536-544]

[1]Chen,Hong;Chen,Feihong;Liu,Nannan;Wang,Xinyi;Gou,Shaohua[BioorganicChemistry,2018,vol.81,p.536-544]

Literature

Title: Identification of potent Yes1 kinase inhibitors using a library screening approach.

Journal: Bioorganic & medicinal chemistry letters 20130801

Title: Selectivity, cocrystal structures, and neuroprotective properties of leucettines, a family of protein kinase inhibitors derived from the marine sponge alkaloid leucettamine B.

Journal: Journal of medicinal chemistry 20121108

Title: Combined inhibition of EGFR and CK2 augments the attenuation of PI3K-Akt-mTOR signaling and the killing of cancer cells.

Journal: Cancer letters 20120901

Title: Identification and validation of inhibitor-responsive kinase substrates using a new paradigm to measure kinase-specific protein phosphorylation index.

Journal: Journal of proteome research 20120706

Title: CK2 inhibitor CX-4945 suppresses DNA repair response triggered by DNA-targeted anticancer drugs and augments efficacy: mechanistic rationale for drug combination therapy.

Journal: Molecular cancer therapeutics 20120401

Title: Structure-based design of novel potent protein kinase CK2 (CK2) inhibitors with phenyl-azole scaffolds.

Journal: Journal of medicinal chemistry 20120322

Title: Synthesis and SAR of inhibitors of protein kinase CK2: novel tricyclic quinoline analogs.

Journal: Bioorganic & medicinal chemistry letters 20120101

Title: Antitumoral activity of allosteric inhibitors of protein kinase CK2.

Journal: Oncotarget 20111201

Title: 7-(4H-1,2,4-Triazol-3-yl)benzo[c][2,6]naphthyridines: a novel class of Pim kinase inhibitors with potent cell antiproliferative activity.

Journal: Bioorganic & medicinal chemistry letters 20111115

Title: Protein kinase CK2 modulates IL-6 expression in inflammatory breast cancer.

Journal: Biochemical and biophysical research communications 20111111

Title: Unprecedented selectivity and structural determinants of a new class of protein kinase CK2 inhibitors in clinical trials for the treatment of cancer.

Journal: Biochemistry 20111004

Title: Pre-clinical characterization of CX-4945, a potent and selective small molecule inhibitor of CK2 for the treatment of cancer.

Journal: Molecular and cellular biochemistry 20111001

Title: Discovery and SAR of 5-(3-chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic acid (CX-4945), the first clinical stage inhibitor of protein kinase CK2 for the treatment of cancer.

Journal: Journal of medicinal chemistry 20110127

Title: Structural basis of CX-4945 binding to human protein kinase CK2.

Journal: FEBS letters 20110103

Title: Structural determinants of CX-4945 derivatives as protein kinase CK2 inhibitors: a computational study.

Journal: International journal of molecular sciences 20110101

Title: CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy.

Journal: Cancer research 20101215

Title: Siddiqui-Jain A, et al. CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy. Cancer Res. 2010 Dec 15;70(24):10288-98.

Title: Buontempo F, et al. Synergistic cytotoxic effects of PS-341 and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival ER chaperone BIP/Grp78 and turning on the pro-apoptotic NF-κB. Oncotarget. 2016 Jan 12;7(2):1323-40.

Title: Chon HJ, et al. The casein kinase 2 inhibitor, CX-4945, as an anti-cancer drug in treatment of human hematological malignancies. Front Pharmacol. 2015 Mar 31;6:70.

Quotation Request
Company Name:
*
Contact Person:
*
Email:
*
Quantity Required:
*
Country:
Additional Info:
SDS
Related Products of 1009820-21-6
Tags:1009820-21-6 Molecular Formula|1009820-21-6 MDL|1009820-21-6 SMILES|1009820-21-6 5-[(3-Chlorophenyl)amino]benzo[c]2,6-naphthyridine-8-carboxylic acid